

# Giancarlo Bisagni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7680190/publications.pdf>

Version: 2024-02-01

84  
papers

3,674  
citations

218677

26  
h-index

133252

59  
g-index

88  
all docs

88  
docs citations

88  
times ranked

4637  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	7.0	36
2	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.2	17
3	Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 547-547.	1.6	3
4	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 12.	5.2	9
5	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	5.2	6
6	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	2.8	20
7	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021, 154, 21-29.	2.8	8
8	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	10.7	41
9	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 827625.	2.8	7
10	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	5.1	12
11	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
12	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. <i>Annals of Oncology</i> , 2019, 30, 921-926.	1.2	64
13	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019, 17, 207.	5.5	4
14	Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 504-504.	1.6	10
15	Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 515-515.	1.6	10
16	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 527-527.	1.6	4
17	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 544-544.	1.6	6
18	Abstract P6-17-05: Independent validation of a combined biomarker based on the PAM50 HER2-enriched subtype and ERBB2 mRNA levels following HER2 blockade without chemotherapy in the PerELISA phase II trial. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
20	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 249-256.	10.7	130
21	Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancerâ€”The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial. <i>JAMA Oncology</i> , 2018, 4, 302.	7.1	115
22	Prognostic impact of interval breast cancer detection in women with pT1a NOMO breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study. <i>European Journal of Cancer</i> , 2018, 88, 10-20.	2.8	2
23	Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. <i>European Journal of Cancer</i> , 2018, 105, 61-70.	2.8	8
24	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 507-507.	1.6	6
25	Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH. <i>Breast</i> , 2017, 34, 65-72.	2.2	15
26	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2+ breast cancer: results from two prospective trials. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 295-302.	2.5	17
27	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39
28	NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study. <i>Breast</i> , 2017, 36, S51-S52.	2.2	0
29	Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. <i>Breast Cancer Research</i> , 2017, 19, 106.	5.0	103
30	Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study. <i>Cancer Research</i> , 2017, 77, P4-21-39-P4-21-39.	0.9	4
31	9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.. <i>Journal of Clinical Oncology</i> , 2017, 35, 501-501.	1.6	26
32	Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 515-515.	1.6	3
33	Abstract P1-09-12: Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit. , 2017, , .		0
34	Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1028-1028.	1.6	0
35	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016, 11, e0156221.	2.5	2
36	Relationship between HER-2 amplification and tumor infiltrating lymphocytes in breast cancer patients treated with neoadjuvant trastuzumab. <i>Annals of Oncology</i> , 2016, 27, iv64.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. <i>Pharmacogenomics Journal</i> , 2016, 16, 472-477.	2.0	22
38	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. <i>Annals of Oncology</i> , 2016, 27, 1867-1873.	1.2	109
39	A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. <i>Future Oncology</i> , 2016, 12, 2589-2602.	2.4	6
40	Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 211-221.	4.4	33
41	Abstract P2-08-03: Survival analysis of the prospective randomized Cher-Lob study: Correlation with tumor infiltrating lymphocytes. , 2016, , .		2
42	ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 502-502.	1.6	9
43	Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 529-529.	1.6	0
44	HER2-amplification level and tumor-infiltrating lymphocytes in breast cancer patients treated with neoadjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , 2016, 34, 596-596.	1.6	0
45	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pNO Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0136731.	2.5	11
46	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015, 20, 1001-1010.	3.7	85
47	Preoperative Carboplatinâ€“Paclitaxelâ€“Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 2881-2887.	1.5	14
48	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2â€“2 factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1863-1872.	13.7	164
49	Abstract PD1-1: Tumor infiltrating lymphocytes and correlation with outcome in the Cher-LOB study. , 2015, , .		6
50	Abstract P5-19-25: Multi-institutional retrospective analysis of clinical and pathological factors predicting resistance to lapatinib-based therapy in HER2 positive metastatic breast cancer (HER2+ MBC). , 2015, , .		0
51	Abstract P5-18-05: The Promher Study: An observational Italian study on HER2+ve, pT1a-b, pNO, MO breast cancer (BC) patients (pts). , 2015, , .		0
52	Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11605-e11605.	1.6	0
53	Prognostic impact of HER2 overexpression/amplification in women with pT1a NO MO breast cancer with known screening status: First results from a multicenter population-based cancer registry study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 594-594.	1.6	23
54	Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. <i>British Journal of Cancer</i> , 2014, 110, 1133-1138.	6.4	10

#	ARTICLE	IF	CITATIONS
55	Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1050-1057.	1.6	46
56	Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. <i>Pharmacogenomics Journal</i> , 2014, 14, 14-19.	2.0	21
57	The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1051-1057.	2.3	17
58	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1229-1240.	2.5	8
59	Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 167-174.	2.5	19
60	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013, 22, 470-475.	2.2	13
61	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1436-1441.	1.2	31
62	Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1989-1995.	1.6	330
63	Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression. <i>Cancer Genetics</i> , 2012, 205, 630-635.	0.4	9
64	Abstract P5-12-05:9Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. , 2010, , .		0
65	Abstract P2-17-01: Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer. , 2010, , .		0
66	Prospective, Multicenter, Randomized Trial of a New Organizational Modality for Providing Information and Support to Cancer Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 1794-1799.	1.6	17
67	Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 773-775.	1.1	75
68	Phase II, randomized trial of preoperative epirubicin-paclitaxel+ÂˆÂˆÂˆgefitinib with biomarker evaluation in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 127-134.	2.5	19
69	Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. <i>Journal of the National Cancer Institute</i> , 2008, 100, 388-398.	6.3	123
70	Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/Neu-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1789-1796.	1.6	940
71	Central Nervous System Metastases in HER-2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors. <i>Oncologist</i> , 2007, 12, 766-773.	3.7	132
72	Evaluation of HER-2/Neu Amplification and Other Biological Markers as Predictors of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Primary Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 171-177.	1.3	36

#	ARTICLE	IF	CITATIONS
73	Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate,) Tj ETQq1 1 0.784314 rgBT / Ov long-term outcomes. <i>Annals of Oncology</i> , 2005, 16, 1469-1476.	1.2	9
74	HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results. <i>Clinical Breast Cancer</i> , 2005, 6, 253-259.	2.4	20
75	Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 159-168.	2.5	78
76	Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. <i>Annals of Oncology</i> , 2003, 14, 1258-1263.	1.2	63
77	Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. <i>European Journal of Cancer</i> , 2002, 38, 2279-2288.	2.8	14
78	Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. <i>Cancer</i> , 2002, 95, 228-235.	4.1	9
79	Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial. <i>Breast Cancer Research and Treatment</i> , 1999, 56, 123-130.	2.5	13
80	Comparison of CMF (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) With a Rotational Crossing and a Sequential Intensification Regimen in Advanced Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 593.	1.3	10
81	Cisplatin and VP16 in Metastatic Breast Carcinoma as a Third-Line Chemotherapy: A Randomized Study Comparing Low versus High Doses of Cisplatin. <i>Tumori</i> , 1995, 81, 241-244.	1.1	15
82	Neoadjuvant Chemotherapy or Chemotherapy and Endocrine Therapy in Locally Advanced Breast Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1990, 13, 226-232.	1.3	42
83	Combination Therapy with Platinum and Etoposide of Brain Metastases from Breast Carcinoma. <i>Cancer Investigation</i> , 1990, 8, 327-334.	1.3	124
84	Problems in evaluating response of primary breast cancer to systemic therapy. <i>Breast Cancer Research and Treatment</i> , 1984, 4, 309-313.	2.5	94